How Ipamorelin Works in the Research: Receptor, Pathway, Pulse
Start here
If you have wondered what does ipamorelin peptide do at the level of cells, here is the plain version. Ipamorelin is a tiny five-amino-acid peptide that fits into one specific lock on the pituitary gland, the ghrelin receptor (its technical name is GHS-R1a). The ghrelin receptor is normally triggered by ghrelin, the body's hunger hormone. When ipamorelin flips that switch, the pituitary releases a short pulse of growth hormone [1]. The special thing, proven in 1998, is that it pulls this one lever cleanly: it raises growth hormone without raising the stress hormone cortisol or prolactin, which the older peptides in its class do not manage [1]. Because it works through a different door than peptides like sermorelin and tesamorelin, it is often paired with them. Below, the mechanism step by step, then how it compares to its cousins.
What is ipamorelin peptide
The ipamorelin peptide is a wholly synthetic pentapeptide, five amino acids in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight of about 712 Da [1]. It was derived from the earlier peptide GHRP-1 by removing a central dipeptide, and the unusual building blocks (alpha-aminoisobutyric acid at position 1, plus D-form amino acids) make it resistant to the enzymes that would otherwise break it down [1]. It is not a natural human peptide; it is a designed mimic of ghrelin that targets the ghrelin receptor. Its development code was NNC 26-0161, originated by Novo Nordisk [1].
Step by step: from receptor to growth-hormone pulse
The mechanism is a short chain of events. Ipamorelin binds the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) on pituitary somatotrophs, the growth-hormone-producing cells [1]. That binding activates the Gq/PLC signaling pathway, which raises calcium inside the cell, and the calcium rise triggers release of a stored pulse of growth hormone [1]. In humans, that pulse is a single discrete spike peaking about 40 minutes after dosing, and the peptide is mostly cleared within a couple of hours (terminal half-life around 2 hours) [2]. Downstream, growth hormone can prompt the liver to make IGF-1, though in short rodent studies IGF-1 was not always raised, suggesting some effects are local and pulse-driven [4].
Why it is paired with a GHRH analog
Ipamorelin works through a different pathway than the GHRH analogs, which is the whole point of combining them. GHRH analogs such as CJC-1295 act on the GHRH receptor through the cAMP pathway, while ipamorelin acts on the ghrelin receptor through the calcium pathway [1]. Activating both at once is additive. Supporting the physiology: pulsatile growth-hormone secretion persisted even during continuous CJC-1295 stimulation, so a steady GHRH signal does not flatten the natural rhythm a pulsatile ghrelin-receptor agonist provides [9], and CJC-1295 produces durable IGF-1 elevation [10]. This complementary-pathway logic, not a combination trial, is what underpins the popular pairing [3].
Ipamorelin vs sermorelin
Ipamorelin vs sermorelin is a contrast of two different receptors. Sermorelin is a GHRH analog: it mimics growth-hormone-releasing hormone and acts on the GHRH receptor [1]. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist acting on a different receptor entirely [1]. They raise growth hormone by separate, complementary pathways, which is why a GHRH analog and a ghrelin-receptor agonist are sometimes combined rather than chosen one-or-the-other [9]. A practical regulatory difference: sermorelin had an approved-drug history, whereas ipamorelin has never been approved for any indication [3].
Ipamorelin vs tesamorelin
Ipamorelin vs tesamorelin is the same receptor contrast with a different comparator. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor [1]; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist acting on the ghrelin receptor [1]. Because they work through complementary pathways, they are mechanistically combinable rather than interchangeable [9]. The evidence bases differ sharply: tesamorelin reached regulatory approval for a specific indication, while ipamorelin's only Phase 2 trial missed its endpoint and it has no approved use anywhere [3].